People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Genomenon, Inc. | — | Biotechnology | Series B | $28.8M | $41.9M | 2020 |
| Kumanu, Inc. | — | Other Technology | Series A | $13.3M | $2.2M | 2016 |
David Gregorka at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Gregorka on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Meister | 1 | 12 |
| Michael Klein | 1 | 9 |
| Michael Gross | 1 | 9 |
| Charles Moret | 1 | 4 |
| Patricia Glaza | 1 | 3 |
| Steve Schwartz | 1 | 2 |
| Randy Oostra | 1 | 2 |
| Sean Kearney | 1 | 2 |
| Young Bang | 1 | 1 |
| Robert Carr | 1 | 1 |
| Sonya Sepahban | 1 | 1 |
| John Ternes | 1 | 1 |
| Robert Boylen | 1 | 1 |
| Andrew Gottman | 1 | 1 |
| Steve Escaravage | 1 | 1 |
| Robin Whitney | 1 | 1 |
| Eli Salembier | 1 | 1 |
| Jeffery Bistrong | 1 | 1 |
| Steven Escaravage | 1 | 1 |
| Katherine Harding | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.